Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
103
Recruiting, any sponsor type, condition "COVID-19"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting103
- Completed1,908
103 trials
Showing 1 to 25, recently updated first.
University of California, San DiegoAcademic, hospital or other
NCT05553743 · 5,000 participants (planned) · Start Mar 27, 2014 · Primary completion Mar 2040
Drug: COVID-19 Exposure; Antibiotic · For: Breastfeeding; COVID-19 Infection; COVID-19 Vaccine and 2 more
Sites: San Diego, California
- Improving Vaccine Efficacy for People With Helminth Infection: CORBEVAX in EthiopiaPivotal-lookingRecruiting
University of AarhusAcademic, hospital or other
NCT07948395 · 150 participants (planned) · Start Oct 10, 2026 · Primary completion Apr 30, 2027
Drug: Biological: CORBEVAX · For: Schistosomiasis Mansoni; Hookworm Infection; COVID-19
Sites: Bahir Dar, Ethiopia
- A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06667700 · 3,082 participants (planned) · Start Dec 2, 2024 · Primary completion Jan 26, 2031
Drug: Molnupiravir; Placebo · For: Coronavirus Disease (COVID-19)
Sites: Cullman, Alabama; Paradise Valley, Arizona; Phoenix, Arizona · 230 sites in all
- A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe DiseasePivotal-lookingRecruiting
ShionogiIndustry
NCT07743580 · 2,000 participants (planned) · Start Sep 14, 2026 · Primary completion Jun 30, 2028
Drug: Secutrelvir; Placebo · For: SARS-CoV-2
Sites: Coral Gables, Florida; Hialeah, Florida; Miami, Florida · 52 sites in all
Stanford UniversityAcademic, hospital or other
NCT04579588 · 230 participants (planned) · Start Oct 29, 2020 · Primary completion Apr 2028
Drug: Flu shot · For: Corona Virus Infection; Flu Vaccine; Immunity
Sites: Palo Alto, California
- Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07890454 · 6,000 participants (planned) · Start Oct 28, 2026 · Primary completion Dec 28, 2027
Drug: IIV-HD (standalone); NVXC19 (EU licensed, standalone) and 2 more · For: Immunization; Healthy Volunteers; COVID-19 Immunization and 1 more
Sites: Wroclaw, Poland; Gdynia, Poland
IMMUNOe Research CentersIndustry
NCT07932002 · 30 participants (planned) · Start Nov 5, 2025 · Primary completion Jul 31, 2027
Drug: Ruconest · For: Post SARS-CoV2 (COVID-19); Post-Viral Fatigue Syndrome; Post-Viral Disorder (Disorder) and 1 more
Sites: Centennial, Colorado
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgePivotal-lookingRecruiting
ModernaTX, Inc.Moderna (MRNA)
NCT07808697 · 300 participants (planned) · Start Sep 4, 2026 · Primary completion Aug 30, 2029
Drug: mRNA-1283; mRNA-1273 · For: SARS-CoV-2
Sites: Ontario, California; Miami, Florida; Miami Lakes, Florida · 31 sites in all
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsPivotal-lookingRecruiting
ModernaTX, Inc.Moderna (MRNA)
NCT07863635 · 600 participants (planned) · Start Oct 9, 2026 · Primary completion Dec 11, 2026
Drug: mRNA-1273; mRNA-1283 · For: SARS-CoV-2
Sites: Overland Park, Kansas; Louisville, Kentucky; Charlotte, North Carolina · 5 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
Henry M. Jackson Foundation for the Advancement of Military MedicineAcademic, hospital or other
NCT07287137 · 54 participants (planned) · Start Nov 12, 2025 · Primary completion Sep 2027
Drug: Pfizer-BioNTech mRNA COVID-19 vaccine; Novavax recombinant protein vaccine · For: COVID -19; COVID - 19; COVID 19 and 5 more
Sites: Bethesda, Maryland
- Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental OxygenPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05624450 · 3,527 participants (planned) · Start Dec 13, 2022 · Primary completion Nov 4, 2027
Drug: Tozorakimab; Placebo · For: Viral Lung Infection and Acute Respiratory Failure
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 473 sites in all
- SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID DysfunctionPivotal-lookingRecruiting
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
NCT07597902 · 150 participants (planned) · Start Oct 20, 2026 · Primary completion Jun 30, 2028
Drug: Valacyclovir; Celecoxib and 2 more · For: Post-acute Sequelae of COVID-19; Long COVID
Sites: New York, New York
- COVID-19 Booster and IIV Schedule in Immunocompromised HostsPivotal-lookingRecruiting
McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
NCT06599658 · 660 participants (planned) · Start Nov 20, 2024 · Primary completion Jan 31, 2028
Drug: Inactivated influenza vaccine (IIV) at baseline; COVID-19 Vaccines at a 3-month interval and 2 more · For: COVID 19; Influenza; Rheumatoid Arthritis (RA) and 5 more
Sites: Montreal, Canada · 3 sites in all
- DAOIB for the Treatment of Brain FogRecruiting
Chang Gung Memorial HospitalAcademic, hospital or other
NCT05764538 · 40 participants (planned) · Start Feb 27, 2023 · Primary completion Jun 2027
Drug: DAOIB · For: Long COVID
Sites: Kaohsiung City, Taiwan
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy TrialPivotal-lookingRecruiting
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT05587894 · 256 participants (planned) · Start Apr 27, 2023 · Primary completion Dec 31, 2026
Drug: Paxlovid 5 days; Paxlovid 10 days and 1 more · For: COVID-19; Immunodeficiency
Sites: Bordeaux, France; Dijon, France; Lyon, France · 18 sites in all
- Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult ParticipantsPivotal-lookingRecruiting
ShionogiIndustry
NCT07093580 · 128 participants (planned) · Start Jul 29, 2025 · Primary completion Jun 30, 2028
Drug: S-892216-LAI; Placebo · For: Healthy Participants
Sites: Cypress, California; Lenexa, Kansas; Salt Lake City, Utah
- A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe DiseasePivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06679140 · 2,330 participants (planned) · Start Dec 8, 2024 · Primary completion Oct 1, 2027
Drug: ibuzatrelvir; placebo · For: COVID-19 SARS-CoV-2 Infection
Sites: Huntsville, Alabama; Little Rock, Arkansas; Bakersfield, California · 256 sites in all
- LIFT: Life Improvement TrialPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT06366724 · 160 participants (planned) · Start Sep 10, 2024 · Primary completion Sep 2027
Drug: Pyridostigmine; Low-Dose Naltrexone · For: ME/CFS; Long COVID; PASC
Sites: Boston, Massachusetts
- A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely ImmunocompromisedPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07013474 · 300 participants (planned) · Start Jul 14, 2025 · Primary completion Sep 28, 2027
Drug: ibuzatrelvir; remdesivir and 2 more · For: COVID-19 Infection
Sites: Canoga Park, California; Granada Hills, California; La Jolla, California · 159 sites in all
- Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug StudyPivotal-lookingRecruiting
Douglas D. FraserAcademic, hospital or other
NCT06928272 · 348 participants (planned) · Start Sep 10, 2025 · Primary completion Dec 2026
Drug: Pirfenidone; Placebo for pirfenidone and 2 more · For: Long COVID
Sites: San Diego, California; Rio de Janeiro, Brazil; Montreal, Canada · 10 sites in all
Fundación Santa Fe de BogotaAcademic, hospital or other
NCT07856225 · 370 participants (planned) · Start Dec 1, 2025 · Primary completion Jun 1, 2027
Drug: CDK4/6 Inhibitors; Anti-HER2 Therapy · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HER2-Positive Breast Cancer and 1 more
Sites: Bogotá, Colombia
- Nosocomial Respiratory Virus InfectionRecruiting
Hospices Civils de LyonAcademic, hospital or other
NCT06643039 · 1,000 participants (planned) · Start Dec 5, 2024 · Primary completion Jul 5, 2027
Drug: Nasopharyngeal swab · For: Nosocomial Infections
Sites: Bordeaux, France; Dijon, France; Lyon, France · 6 sites in all
- SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)Pivotal-lookingRecruiting
Nancy KlimasAcademic, hospital or other
NCT07021794 · 100 participants (planned) · Start Jul 28, 2025 · Primary completion Sep 30, 2027
Drug: Placebo; Sipavibart · For: Post-COVID / Long-COVID
Sites: Fort Lauderdale, Florida
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVIDPivotal-lookingRecruiting
Wes ElyAcademic, hospital or other
NCT06631287 · 550 participants (planned) · Start Oct 21, 2024 · Primary completion Nov 1, 2026
Drug: Baricitinib · For: Long COVID; Sars-CoV-2 Infection; Coronavirus Infections and 1 more
Sites: Tucson, Arizona; Los Angeles, California; San Francisco, California · 17 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.